Antimicrobial Agents and Novel Vaccines

Vaccines can reduce the prevalence of resistance by reducing the need for antimicrobial use and can reduce its impact by reducing the total number of cases. By reducing the number of pathogens that may be responsible for a particular clinical syndrome, vaccines can permit the use of narrower-spectrum antibiotics for empirical therapy. These effects may be amplified by herd immunity, extending protection to unvaccinated persons in the population. Because much selection for resistance is due to selection on bystander members of the normal flora, vaccination can reduce pressure for resistance even in pathogens not included in the vaccine. Some vaccines have had disproportionate effects on drug-resistant lineages within the target species, a benefit that could be more deliberately exploited in vaccine design.

 

  • Hib conjugate vaccine
  • Respiratory virus vaccine

Related Conference of Antimicrobial Agents and Novel Vaccines

November 21-22, 2024

7th Pathology and Infectious Disease Conference

Dubai, UAE
November 28-29, 2024

20th World Congress on Infection Prevention and Control

Paris, France
March 13-14, 2025

9th International Conference on Rare Diseases

Prague, Czech Republic
March 17-18, 2025

12th International Congress on Infectious Diseases

Berlin, Germany
April 14-15, 2025

15th European Epidemiology and Public Health Congress

Budapest, Hungary
June 02-03, 2025

14th World Congress on Rare Diseases and Orphan Drugs

Amsterdam, Netherlands
June 02-03, 2025

17th Euro-Global Conference on Infectious Diseases

Amsterdam, Netherlands

Antimicrobial Agents and Novel Vaccines Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in